Existing in vitro reports suggest that the herbal nutrition formulation exhibits inhibitory signals against hemolytic phenomena associated with pyogenic streptococci. The core of the next phase of research is not simply to repeat blood agar plate results, but to clarify whether this change stems from bacterial growth inhibition, reduced hemolytic toxin production, or direct neutralization of toxins by the formulation to protect host cells.
Streptolysin O is a class of virulence factors that can form pores on host cell membranes. Experimental studies have shown that neutralizing streptolysin O can reduce host cell damage, improve immune cell clearance capacity, and alleviate tissue lesions in infected animal models; this provides an experimental framework for the "anti-hemolysis—anti-toxicity—organ protection" research chain.
01 Establish a Standardized Anti-Hemolytic Evaluation System
Using human and animal-derived red blood cells, establish quantitative hemolysis experiments under different sample concentrations, different action times, and different toxin doses to measure hemolysis inhibition rate, half-hemolysis concentration, and half-protection concentration.
Experiments should simultaneously include bacterial growth controls, purified toxin controls, positive neutralization controls, and sample color interference controls to distinguish between "inhibition of bacterial growth" and "direct inhibition of hemolysis." Existing research has already established a reproducible red blood cell anti-hemolytic function measurement framework, which can serve as a reference for subsequent methodological validation.
02 Distinguish Between Hemolysin Production Inhibition and Direct Toxin Neutralization
Focus on streptolysin O, streptolysin S, and related virulence factors to detect toxin protein expression, gene transcription, secretion levels, and red blood cell membrane pore formation ability.
Further, use purified hemolysin, toxin-deficient strains, and toxin-function-impaired strains for cross-validation to determine whether the formulation acts on the toxin production stage, the toxin-cell membrane binding stage, or the pore formation stage. Structural changes in hemolysin can significantly reduce its cell binding, pore aggregation, and in vivo toxicity, indicating that these links can serve as clear endpoints for mechanism research.
03 Establish Red Blood Cell and Vascular Endothelial Protection Models
Based on red blood cell experiments, further observe free hemoglobin, lactate dehydrogenase, free heme, haptoglobin, and red blood cell morphological changes to evaluate cell membrane integrity and oxygen transport-related functions.
Simultaneously, establish a vascular endothelial cell model to detect cell permeability, barrier proteins, inflammatory adhesion molecules, and endothelial injury indicators to study the connection between hemolytic products, inflammatory responses, and microcirculatory disorders.
04 Conduct Invasive Infection Animal Model Verification
Establish local infection, bacteremia, or infection-related tissue damage models of pyogenic streptococci, with groups for formulation alone, antibiotics alone, and combined intervention.
Primary observations include bacterial load, hemoglobin decline, free heme, inflammatory factors, tissue necrosis, organ pathology, and survival outcomes to verify whether in vitro anti-hemolytic signals can translate into reduced in vivo toxicity and tissue protection. Existing animal studies have shown that neutralizing streptolysin O can alleviate tissue lesions and improve bacterial clearance, providing direct experimental evidence for this design.
05 Construct a Dynamic Evaluation System for Critical Illness
Critical illness research should not rely solely on individual inflammatory indicators but should establish dynamic endpoints around organ functional disorders caused by infection. It is recommended to continuously record SOFA scores, lactate and lactate clearance, vasopressor use duration, mechanical ventilation time, ventilator-free days, organ failure-free days, and 28-day outcomes.
Sepsis-3 defines sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, using SOFA changes as the quantitative basis for organ function. Therefore, subsequent research should consider "multi-system functional changes" as the primary evaluation object for critical illness.
06 Study Antibiotic Combination and Emergency Treatment Windows
Evaluate whether the formulation, when combined with clinically common anti-infective drugs, can simultaneously reduce pathogen load, hemolytic activity, and inflammatory damage.
Focus on analyzing different administration sequences and time windows to clarify whether it is more suitable for early infection toxicity control, antibiotic assistance, or supportive intervention after organ damage, avoiding the assumption that all critical states follow the same mode of action.
07 Advance Quality Control and Safety Evaluation
Establish raw material sources, production processes, chemical fingerprints, and key component ranges, and compare the anti-hemolytic activity of different batches of samples to form a dual standard of "chemical consistency—biological activity consistency."
Plant compound preparation research requires recording raw material ratios, extraction processes, time and temperature, and batch quality, and retaining representative samples for subsequent pharmacological and toxicological review.